Nykredit A S Acquires New Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Nykredit A/S acquired 36,943 shares of IDEXX Laboratories during the second quarter, valued at approximately $19.45 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly earnings of $4.27 per share, exceeding estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company reaffirmed fiscal 2026 EPS guidance of $14.69–$14.94.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $747 price target, although several firms have issued neutral or downgraded ratings. Shares recently traded at $511.65, well below their 12-month high of $769.98.

Nykredit A S bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 36,943 shares of the company's stock, valued at approximately $19,448,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. SHP Wealth Management acquired a new position in IDEXX Laboratories in the 4th quarter valued at approximately $26,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the second quarter worth $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after purchasing an additional 32 shares during the period. Wormser Freres Gestion grew its stake in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Finally, Arlington Trust Co LLC grew its stake in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock worth $32,000 after purchasing an additional 19 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $511.65 on Friday. The company has a market capitalization of $40.31 billion, a PE ratio of 35.98, a P/E/G ratio of 2.73 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The firm has a fifty day simple moving average of $550.37 and a 200 day simple moving average of $561.59.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. The business's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on IDXX shares. Citigroup raised their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. UBS Group upped their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings cut IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, August 27th. Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.